In our view, the “prodrugging” of the [Cp*Rh]2+ scaffold into the cancer cells could represent a paradigm change since one can take advantage of Tyr conjugation selectivity to hit the protein substrates of PKs, and blocking the associated kinase-dependent pathways. The gene discussed is ARAF; the disease is cancer.